Article Figures & Data
Figures
- FIGURE 1.
Patient with history of carcinoma of left lung with left axillary lymph node metastases. 18F-FDG PET depicted other unsuspected metastatic sites in both axilla (arrow, right panel) and paratracheal nodes (arrow, center panel).
- FIGURE 2.
Patient with right lower lobe nodule on CT (not shown) and adrenal mass on right side. 18F-FDG PET shows primary neoplasm in right lower lobe (arrow, left and right panels) and right adrenal gland metastases (arrow, middle panel).
- FIGURE 3.
18F-FDG PET in presurgical staging of patients with colorectal cancer and hepatic metastases. This patient presented with history of adenocarcinoma of sigmoid colon and large liver lesion found on CT. PET showed liver metastases but no disease elsewhere. Patient was then considered for liver resection.
- FIGURE 4.
Patient with history of squamous cell carcinoma of oropharynx who was sent for PET scan to assess response to treatment. PET scan showed 2 new lesions: 1 intrapulmonary (arrow, middle panel) and 1 in right upper ribs (arrow, left panel). In addition, primary tumor appeared unchanged.
- FIGURE 5.
PET in staging of breast cancer. This patient presented with newly diagnosed breast carcinoma with suspected liver metastases. In addition, PET showed extensive lymph node involvement in right axilla (arrow), neck (bilaterally), and mediastinum (arrowhead).
Tables
Study No. of patients Change in management Beets et al. (25) 14/23 Avoided surgery in 6 patients Showed pelvic recurrence in 1 patient with rising carcinoembryonic antigen level Excluded pelvic recurrence in 3 patients Correctly depicted pelvic recurrence in 4 patients with equivocal findings on CT Ogunbiyi et al. (24) 10/58 Detected multiple hepatic lesions Schiepers et al. (54) 11/76 Detected 14 unexpected new lesions outside liver in 10 patients Found primary breast cancer in 1 patient Valk et al. (23) 25/78 Resulted in per-patient savings of $3,003 Tumor type Results Study Mesothelioma Sensitivity, 91% Bénard et al. (55) Specificity, 100% Hepatic tumors Earlier depiction of response to therapy with 18F-FDG than with CT or tumor markers Nagata et al. (56) Germ cell carcinoma Accuracy of 90% in seminomas and 81% in nonseminomas Cremerius et al. (57) Musculoskeletal sarcoma Sensitivity, 81% Adler et al. (58) Specificity, 100%
